Aerpio Pharmaceuticals Inc. (ARPO)’s Financial Results Comparing With Vericel Corporation (NASDAQ:VCEL)

Aerpio Pharmaceuticals Inc. (NASDAQ:ARPO) and Vericel Corporation (NASDAQ:VCEL) are two firms in the Biotechnology that compete against each other. Below is a comparison of their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aerpio Pharmaceuticals Inc. 1 1.55 N/A -0.36 0.00
Vericel Corporation 18 6.86 N/A -0.09 0.00

Demonstrates Aerpio Pharmaceuticals Inc. and Vericel Corporation earnings per share (EPS), top-line revenue and valuation.

Profitability

Table 2 demonstrates the net margins, return on equity and return on assets of Aerpio Pharmaceuticals Inc. and Vericel Corporation.

Net Margins Return on Equity Return on Assets
Aerpio Pharmaceuticals Inc. 0.00% -20.5% -17.7%
Vericel Corporation 0.00% -3.4% -2.6%

Liquidity

The Current Ratio and a Quick Ratio of Aerpio Pharmaceuticals Inc. are 13.8 and 13.8. Competitively, Vericel Corporation has 8.5 and 8.2 for Current and Quick Ratio. Aerpio Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Vericel Corporation.

Analyst Ratings

Aerpio Pharmaceuticals Inc. and Vericel Corporation Ratings and Recommendations are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Aerpio Pharmaceuticals Inc. 0 0 0 0.00
Vericel Corporation 0 0 1 3.00

Vericel Corporation on the other hand boasts of a $24 average price target and a 49.35% potential upside.

Institutional & Insider Ownership

Aerpio Pharmaceuticals Inc. and Vericel Corporation has shares owned by institutional investors as follows: 23.4% and 89%. 1.1% are Aerpio Pharmaceuticals Inc.’s share owned by insiders. Insiders Comparatively, owned 0.5% of Vericel Corporation shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aerpio Pharmaceuticals Inc. 0.13% -8.73% -22.06% -79.51% -80.37% -53.24%
Vericel Corporation 1.59% 2.63% 15.04% 13.27% 91.2% 9.89%

For the past year Aerpio Pharmaceuticals Inc. had bearish trend while Vericel Corporation had bullish trend.

Summary

On 7 of the 8 factors Vericel Corporation beats Aerpio Pharmaceuticals Inc.

Aerpio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company is headquartered in Cincinnati, Ohio. Aerpio Pharmaceuticals, Inc.(OTCPK:ARPO) operates independently of Akebia Therapeutics, Inc. as of December 22, 2011.

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. It markets three autologous cell therapy products, including Carticel and MACI, which are used for the treatment of cartilage defects in the knee; and Epicel, a permanent skin replacement that is used for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area in the United States. The company also develops ixmyelocel-T, which is in Phase IIb clinical trial, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.